ATOR-1144 / Alligator Biosci - LARVOL DELTA

ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells (AACR 2019) - "In conclusion, ATOR-1144 is a first-in-class bispecific tumor directed antibody targeting CTLA-4 and GITR. ATOR-1144 acts through several mechanisms, including depletion of Tregs, activation of effector T cells and activation of NK cells for enhanced Treg depletion and tumor cell killing."

Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects (PRNewswire) - “Alligator Bioscience…announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the scientific conference AACR (American Association for Cancer Research), held in Atlanta on March 29 - April 3, 2019….The new preclinical data demonstrate that ATOR-1144 works through several pathways: activation of effector T cells, depletion of regulatory T cells (Tregs) and tumor cells and activation of NK (natural killer) cells, with potential for enhanced tumor cell killing.”

Preclinical